Do representatives have to report adverse events for competitor products?

Pharmaceutical companies must ensure that their staff are trained including on relevant pharmacovigilance requirements. If a representative is advised of an adverse event with a competitor medicine they should as a minimum advise the health professional that this should be reported via the yellow card scheme. Clause 9.2